L'IFEZ, Hanlim Pharmaceutical et Incheon TP signent un protocole d'accord pour la découverte de startups bio

The Incheon Free Economic Zone Authority, Hanlim Pharmaceutical, and Incheon Technopark (ITP) signed a business accord on the 22nd to discover and nurture startups in the bio sector.

Under this accord, the institutions plan to identify startups with technologies demanded by the industrie and support product validation and commercialization.

The key contents of the accord include discovering and fostering innovant startups through Hanlim Pharmaceutical's demand technology identification and cooperative partner programs, establishing a cooperative framework to support on-site validation for startups, and providing continuous growth support through linkage with Incheon Startup Park programme de soutiens.

Hanlim Pharmaceutical is a leading company specializing in hypertension, osteoporosis, and pharmaceutique ophtalmiques, ranking first nationalally in pharmaceutique ophtalmique production capacity.

In June of l'année dernière, l'entreprise registered as an accelerator (startup planner) to focus on investing in and nurturing bio startups and promoting co-growth, participating in recherche et développement conjoints for global pharmaceutique development as a strategic investisseur (SI).

En particulier, after signing an investissement accord worth KRW 15 billion with Incheon Startup Park resident company RudaCure Inc., Hanlim Pharmaceutical has been actively supporting the development of RCI001, the traitement de la sécheresse oculaire.

전자신문